Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
Di Biagio A, Riccardi N, Taramasso L, Capetti A, Cenderello G, Signori A, Vitiello P, Guerra M, de Socio GV, Cassola G, Quirino T, Viscoli C. Di Biagio A, et al. Among authors: guerra m. Int J Antimicrob Agents. 2016 Nov;48(5):551-554. doi: 10.1016/j.ijantimicag.2016.07.009. Epub 2016 Aug 17. Int J Antimicrob Agents. 2016. PMID: 27566908
Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapy.
Di Biagio A, Parisini A, Bruzzone B, Prinapori R, Lauriola M, Paolucci S, Signori A, Barresi R, Icardi G, Calderisi S, Meini G, Dentone C, Cenderello G, Guerra M, Maccabruni A, Rusconi S, Viscoli C. Di Biagio A, et al. Among authors: guerra m. HIV Clin Trials. 2014 Jan-Feb;15(1):45-50. doi: 10.1310/hct1501-45. HIV Clin Trials. 2014. PMID: 24518213
CD8+CD28-CD127loCD39+ regulatory T-cell expansion: A new possible pathogenic mechanism for HIV infection?
Fenoglio D, Dentone C, Signori A, Di Biagio A, Parodi A, Kalli F, Nasi G, Curto M, Cenderello G, De Leo P, Bartolacci V, Orofino G, Nicolini LA, Taramasso L, Fiorillo E, Orrù V, Traverso P, Bruzzone B, Ivaldi F, Mantia E, Guerra M, Negrini S, Giacomini M, Bhagani S, Filaci G. Fenoglio D, et al. Among authors: guerra m. J Allergy Clin Immunol. 2018 Jun;141(6):2220-2233.e4. doi: 10.1016/j.jaci.2017.08.021. Epub 2017 Nov 2. J Allergy Clin Immunol. 2018. PMID: 29103633 Free article.
Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
Dentone C, Sterrantino G, Signori A, Cenderello G, Guerra M, De Leo P, Bartolacci V, Mantia E, Orofino G, Giacomini M, Bruzzone B, Francisci D, Di Biagio A; MARHIV Study Group. Dentone C, et al. Among authors: guerra m. Int J STD AIDS. 2017 Oct;28(11):1067-1073. doi: 10.1177/0956462416687828. Epub 2017 Jan 31. Int J STD AIDS. 2017. PMID: 28142395
Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL.
Dentone C, Fenoglio D, Signori A, Cenderello G, Parodi A, Bozzano F, Guerra M, De Leo P, Bartolacci V, Mantia E, Orofino G, Kalli F, Marras F, Fraccaro P, Giacomini M, Cassola G, Bruzzone B, Ferrea G, Viscoli C, Filaci G, De Maria A, Di Biagio A. Dentone C, et al. Among authors: guerra m. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19718. doi: 10.7448/IAS.17.4.19718. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397464 Free PMC article.
The ligurian human immunodeficiency virus clinical network: a web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials.
Fraccaro P, Pupella V, Gazzarata R, Dentone C, Cenderello G, De Leo P, Bozzano F, Casalino Finocchio G, De Maria A, Fenoglio D, Filaci G, Guerra M, Di Biagio A, Mantia E, Orofino G, Ferrea G, Viscoli C, Giacomini M. Fraccaro P, et al. Among authors: guerra m. Med 2 0. 2013 Aug 13;2(2):e5. doi: 10.2196/med20.2712. eCollection 2013 Jul-Dec. Med 2 0. 2013. PMID: 25075240 Free PMC article.
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Ascione A, et al. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. Infection. 2018. PMID: 29808463
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, Antinori A, Bruno R, Bruno S, Chirianni A, Gaeta GB, Giannini EG, Merli M, Messina V, Montilla S, Perno CF, Puoti M, Raimondo G, Rendina M, Silberstein FC, Villa E, Zignego AL, Pani L, Craxì A; ABACUS study group; AIFA team. Petta S, et al. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434. doi: 10.1016/S2468-1253(17)30048-1. Epub 2017 Apr 10. Lancet Gastroenterol Hepatol. 2017. PMID: 28497758
1,596 results